← Leaderboards
Kara Lynn Davis
Stanford University
$3,206,400
Attributed
$3,505,691
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $762.2K · FY2017–25$1M$750K$500K$250K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,505,691 · 2
By mechanism
R01$3,056,754 · 1
R21$448,937 · 1
Top collaborators
- Matthew Spitzer2 shared
- Joy Y Wu2 shared
Most similar at Stanford University
Same institution · by research overlap
- Joseph C Wu$80,370,369
- William H Robinson$16,848,609
- Matthew J. Frank$844,890
- Nidhi Bhutani$8,915,723
- Melody Smith$835,380
Others in their field
Other Emerging Leaders on “Response”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$195,683,539
- Kimberly Smith · Ppd Development Lp$115,671,664
- Paul F Gallagher · Woods Hole Oceanographic Institution$92,619,872
- Kevin Urdahl · Seattle Children'S Hospital$84,741,409
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,439,892
- Ted Ross · University Of Georgia$70,992,558
Research focus
ResponseLeukemiaPathway InteractionsSignal TransductionCellsTargeted TreatmentSamplingPhenotypePublishingMutationDiagnosisClinical TrialsRelapseComplexB-LymphocytesGeneticFutureIndividual PatientDiagnosticMolecularLeukemic CellBiologyCreb1 GeneCancer Etiology
Grant awards (8)
Predicting Relapse at the Time of Diagnosis in Acute Lymphoblastic Leukemia$570,059
R01 · FY2025 · CA · contact PI
Predicting Relapse at the Time of Diagnosis in Acute Lymphoblastic Leukemia$547,763
R01 · FY2024 · CA · contact PI
Predicting Relapse at the Time of Diagnosis in Acute Lymphoblastic Leukemia$572,741
R01 · FY2023 · CA · contact PI
Predicting Relapse at the Time of Diagnosis in Acute Lymphoblastic Leukemia$604,026
R01 · FY2022 · CA · contact PI
Predicting Relapse at the Time of Diagnosis in Acute Lymphoblastic Leukemia$615,576
R01 · FY2021 · CA · contact PI
Dissecting Single-cell Response or Resistance to Novel Combination Therapy in AML using Mass Cytometry$146,589
R01 · FY2021 · CA · contact PI
Single-cell High-dimensional Characterization of the Bone Marrow Microenvironment in Health and Disease$197,763
R21 · FY2018 · AG
Single-cell High-dimensional Characterization of the Bone Marrow Microenvironment in Health and Disease$251,174
R21 · FY2017 · AG